Providing Consultative DMPK Solutions Bridging Drug Discovery and Development
21 Nov 2013

XenoTech and XenoGesis work together to facilitate outsourced drug metabolism and pharmacokinetics (DMPK) studies from early stage drug discovery through development and beyond. The partnership was developed to help mitigate the risk and cost associated with clinical failure. Efficacy and safety are now the leading causes of attrition and are linked to drug exposure in target and off-target tissues. While pharmacokinetics is no longer the leading cause of failure, a drug’s exposure is driven by its pharmacokinetic properties and ultimately remains critical for successful pharmacodynamics and safety. This webinar will showcase the consultative basis of the DMPK CRO alliance and highlight the capabilities with real-life examples of our unique combination of expertise.

Xenotech LLC



Show    per page
1 of 10 Page     1 2 3  ... Next 
Avoiding Bottlenecks When Validating Your Laboratory Instrument and Information Systems20 Aug 2014Read
A New Concept in Metabolic Studies: How Personalized 'Sportomics' Bridges Bench and Clinical Science24 Jul 2014Read
Process development and optimisation using ambr250™ for mammalian and microbial processes2 Jul 2014Read
Why does ice cream taste smooth or gritty? It depends on the rheology!30 Jun 2014Read
Masterclass 4: Configuring optical parameters for laser diffraction particle size analysis30 Jun 2014Read
The Science of Beauty - Characterizing Hyaluronic Acid - the molecule behind anti-aging creams30 Jun 2014Read
Polymer solution characterization part 3: Branching out! Intrinsically useful views on polymer structure30 Jun 2014Read
Optical Properties of Organic Compounds: obtaining the refractive index and absorption values for use in laser diffraction particle size analysis30 Jun 2014Read
Configuring optical parameters for laser diffraction particle size analysis19 Jun 2014Read
Click Chemistry Reagents Labeled with DBCO Groups Allow for Copper-Free Biomolecule Labeling Reactions18 Jun 2014Read